AU2016226087A1 - ETV2 and uses thereof - Google Patents
ETV2 and uses thereof Download PDFInfo
- Publication number
- AU2016226087A1 AU2016226087A1 AU2016226087A AU2016226087A AU2016226087A1 AU 2016226087 A1 AU2016226087 A1 AU 2016226087A1 AU 2016226087 A AU2016226087 A AU 2016226087A AU 2016226087 A AU2016226087 A AU 2016226087A AU 2016226087 A1 AU2016226087 A1 AU 2016226087A1
- Authority
- AU
- Australia
- Prior art keywords
- human
- etv2
- human animal
- blastocyst
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101000813735 Homo sapiens ETS translocation variant 2 Proteins 0.000 title claims abstract description 97
- 102100039579 ETS translocation variant 2 Human genes 0.000 title claims abstract description 82
- 210000002459 blastocyst Anatomy 0.000 claims abstract description 69
- 210000000130 stem cell Anatomy 0.000 claims abstract description 32
- 210000000287 oocyte Anatomy 0.000 claims abstract description 17
- 210000004102 animal cell Anatomy 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- 230000035772 mutation Effects 0.000 claims abstract description 12
- 238000010374 somatic cell nuclear transfer Methods 0.000 claims abstract description 12
- 102000048856 human ETV2 Human genes 0.000 claims abstract description 8
- 230000003213 activating effect Effects 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 101
- 210000000056 organ Anatomy 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 30
- 241001465754 Metazoa Species 0.000 claims description 23
- 210000001519 tissue Anatomy 0.000 claims description 20
- 108700028369 Alleles Proteins 0.000 claims description 16
- 238000012217 deletion Methods 0.000 claims description 14
- 230000037430 deletion Effects 0.000 claims description 14
- 101100012008 Homo sapiens ETV2 gene Proteins 0.000 claims description 11
- 241000283690 Bos taurus Species 0.000 claims description 10
- 241000283707 Capra Species 0.000 claims description 10
- 210000000601 blood cell Anatomy 0.000 claims description 10
- 241000283073 Equus caballus Species 0.000 claims description 9
- 210000001772 blood platelet Anatomy 0.000 claims description 9
- 210000003038 endothelium Anatomy 0.000 claims description 9
- 210000003743 erythrocyte Anatomy 0.000 claims description 8
- 210000000265 leukocyte Anatomy 0.000 claims description 8
- 210000004700 fetal blood Anatomy 0.000 claims description 6
- 210000002950 fibroblast Anatomy 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 4
- 210000000472 morula Anatomy 0.000 claims description 4
- 230000013011 mating Effects 0.000 claims description 3
- 210000004504 adult stem cell Anatomy 0.000 claims description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- 210000002894 multi-fate stem cell Anatomy 0.000 claims 1
- 210000003954 umbilical cord Anatomy 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 description 45
- 230000003511 endothelial effect Effects 0.000 description 44
- 210000002257 embryonic structure Anatomy 0.000 description 39
- 230000003394 haemopoietic effect Effects 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 241000282887 Suidae Species 0.000 description 18
- 210000001161 mammalian embryo Anatomy 0.000 description 18
- 238000010459 TALEN Methods 0.000 description 17
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 16
- 238000011161 development Methods 0.000 description 16
- 230000018109 developmental process Effects 0.000 description 16
- 230000004069 differentiation Effects 0.000 description 14
- 210000004940 nucleus Anatomy 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 10
- 230000002526 effect on cardiovascular system Effects 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 238000010362 genome editing Methods 0.000 description 9
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 8
- 210000002242 embryoid body Anatomy 0.000 description 8
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 7
- 101150005295 GATA2 gene Proteins 0.000 description 7
- 101100012009 Mus musculus Etv2 gene Proteins 0.000 description 7
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 208000018706 hematopoietic system disease Diseases 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000001082 somatic cell Anatomy 0.000 description 7
- 210000005166 vasculature Anatomy 0.000 description 7
- 101150077461 Etv2 gene Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000012173 estrus Effects 0.000 description 5
- 208000014951 hematologic disease Diseases 0.000 description 5
- 230000001776 parthenogenetic effect Effects 0.000 description 5
- 102100038566 Endomucin Human genes 0.000 description 4
- 108010061228 Sialomucins Proteins 0.000 description 4
- 210000001643 allantois Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000001174 endocardium Anatomy 0.000 description 4
- 210000002304 esc Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 210000001325 yolk sac Anatomy 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 108700005075 Regulator Genes Proteins 0.000 description 3
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000004681 ovum Anatomy 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000004952 blastocoel Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000009762 endothelial cell differentiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 101150003286 gata4 gene Proteins 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003990 molecular pathway Effects 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- VWAUPFMBXBWEQY-ANULTFPQSA-N Altrenogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC=C)C=C3)C3=C21 VWAUPFMBXBWEQY-ANULTFPQSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 108700029231 Developmental Genes Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101000574648 Homo sapiens Retinoid-inducible serine carboxypeptidase Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101150114527 Nkx2-5 gene Proteins 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 101150044441 PECAM1 gene Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009557 abdominal ultrasonography Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229960000971 altrenogest Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009110 definitive therapy Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 238000012835 hanging drop method Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229940090213 lutalyse Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000021368 organ growth Effects 0.000 description 1
- 238000010373 organism cloning Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000015031 pancreas development Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 101150065190 term gene Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229940060693 tiletamine / zolazepam Drugs 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8778—Swine embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0604—Whole embryos; Culture medium therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562127330P | 2015-03-03 | 2015-03-03 | |
| US62/127,330 | 2015-03-03 | ||
| PCT/US2016/020768 WO2016141234A1 (en) | 2015-03-03 | 2016-03-03 | Etv2 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016226087A1 true AU2016226087A1 (en) | 2017-10-26 |
Family
ID=56848633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016226087A Abandoned AU2016226087A1 (en) | 2015-03-03 | 2016-03-03 | ETV2 and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11673928B2 (enExample) |
| EP (1) | EP3264891A4 (enExample) |
| JP (1) | JP2018506984A (enExample) |
| KR (1) | KR102684690B1 (enExample) |
| CN (1) | CN108024522A (enExample) |
| AU (1) | AU2016226087A1 (enExample) |
| BR (1) | BR112017018932A2 (enExample) |
| CA (1) | CA2978457A1 (enExample) |
| CL (1) | CL2017002226A1 (enExample) |
| IL (1) | IL254241A0 (enExample) |
| MX (1) | MX2017011345A (enExample) |
| PH (1) | PH12017501589A1 (enExample) |
| RU (1) | RU2017132331A (enExample) |
| SG (1) | SG11201707151YA (enExample) |
| WO (1) | WO2016141234A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017132331A (ru) | 2015-03-03 | 2019-04-03 | Реджентс Оф Зэ Юниверсити Оф Миннесота | Etv2 и его применения |
| EP3316898A4 (en) | 2015-06-30 | 2019-02-27 | Regents of the University of Minnesota | HUMANIZED SKELETON MUSCLE |
| EP3316899A4 (en) | 2015-06-30 | 2019-04-03 | Regents of the University of Minnesota | HUMANIZED CARDIAC MUSCLE |
| CN110520167B (zh) * | 2017-02-03 | 2023-03-24 | 康奈尔大学 | 稳定的三维血管和形成其的方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2242666A1 (en) | 1996-01-09 | 1997-07-17 | The Regents Of The University Of California | Ungulate embryonic stem-like cells, methods of making and using the cells to produce transgenic ungulates |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| CN1241210A (zh) | 1996-10-11 | 2000-01-12 | 得克萨斯农业及机械体系综合大学 | 产生原生殖细胞和转基因动物物种的方法 |
| WO2003034818A1 (en) * | 2001-10-24 | 2003-05-01 | Chugai Seiyaku Kabushiki Kaisha | Sgrf genetically modified nonhuman animal |
| US20040133931A1 (en) | 2003-01-08 | 2004-07-08 | Gavin William G. | Method and system for fusion and activation following nuclear transfer in reconstructed embryos |
| US20050125853A1 (en) * | 2002-03-22 | 2005-06-09 | St. Jude Children's Resarch Hospital | Method for generating genetically modified animals |
| CA2488725A1 (en) | 2002-07-03 | 2004-01-15 | Su Qian | Agouti-related protein deficient cells, non-human transgenic animals and methods of selecting compounds which regulate energy metabolism |
| GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
| WO2006014551A2 (en) | 2004-07-06 | 2006-02-09 | Michigan State University | In vivo methods for effecting tissue specific differentiation of embryonic stem cells |
| AU2008205278B2 (en) | 2007-01-11 | 2014-06-12 | University Of Pittsburgh | Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using the same |
| JP2010516258A (ja) * | 2007-01-20 | 2010-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ反応性タンパク質（ｃｒｐ）ノックアウトマウス |
| JPWO2008102602A1 (ja) | 2007-02-22 | 2010-05-27 | 国立大学法人 東京大学 | Ｂｌａｓｔｏｃｙｓｔｃｏｍｐｌｅｍｅｎｔａｔｉｏｎを利用した臓器再生法 |
| JP5688788B2 (ja) * | 2008-02-22 | 2015-03-25 | 国立大学法人 東京大学 | 遺伝子改変による致死性表現型を持つ動物の繁殖用ファウンダー動物作製法 |
| GB2475656B (en) | 2008-08-22 | 2013-04-24 | Univ Tokyo | Organ regeneration method utilizing ips cell and blastocyst complementation |
| WO2010108126A2 (en) | 2009-03-19 | 2010-09-23 | Fate Therapeutics, Inc. | Reprogramming compositions and methods of using the same |
| WO2010133686A1 (en) | 2009-05-20 | 2010-11-25 | Cardio3 Biosciences S.A. | Parmaceutical composition for the treatment of heart diseases. |
| PT2702160T (pt) | 2011-04-27 | 2020-07-30 | Amyris Inc | Métodos para modificação genómica |
| EP2714892B1 (en) | 2011-06-02 | 2018-02-21 | President and Fellows of Harvard College | Methods and uses for ex vivo tissue culture systems |
| JP6083877B2 (ja) | 2011-11-18 | 2017-02-22 | 国立大学法人京都大学 | 多能性幹細胞から骨格筋細胞への分化誘導方法 |
| IL221187A (en) | 2012-07-30 | 2017-01-31 | Adom Advanced Optical Tech Ltd | A system to perform optical tomography in two 2D beams |
| US20140115728A1 (en) | 2012-10-24 | 2014-04-24 | A. Joseph Tector | Double knockout (gt/cmah-ko) pigs, organs and tissues |
| US11377639B2 (en) | 2013-11-15 | 2022-07-05 | Wisconsin Alumni Research Foundation | Lineage reprogramming to induced cardiac progenitor cells (iCPC) by defined factors |
| MX2016014066A (es) | 2014-04-28 | 2017-05-03 | Recombinetics Inc | Edicion de genes multiples en cerdos. |
| RU2017132331A (ru) | 2015-03-03 | 2019-04-03 | Реджентс Оф Зэ Юниверсити Оф Миннесота | Etv2 и его применения |
| EP3316899A4 (en) | 2015-06-30 | 2019-04-03 | Regents of the University of Minnesota | HUMANIZED CARDIAC MUSCLE |
| EP3316898A4 (en) | 2015-06-30 | 2019-02-27 | Regents of the University of Minnesota | HUMANIZED SKELETON MUSCLE |
| CN108697067A (zh) | 2015-10-27 | 2018-10-23 | 明尼苏达大学评议会 | 嵌合胚胎-辅助的器官制备的组合物和方法 |
| CN108125943A (zh) | 2018-01-17 | 2018-06-08 | 云南省第二人民医院 | 前胡醇当归脂作为制备抗动脉粥样硬化药物的应用 |
-
2016
- 2016-03-03 RU RU2017132331A patent/RU2017132331A/ru not_active Application Discontinuation
- 2016-03-03 MX MX2017011345A patent/MX2017011345A/es unknown
- 2016-03-03 EP EP16759528.9A patent/EP3264891A4/en not_active Ceased
- 2016-03-03 US US15/554,585 patent/US11673928B2/en active Active
- 2016-03-03 JP JP2017546061A patent/JP2018506984A/ja active Pending
- 2016-03-03 CN CN201680024200.8A patent/CN108024522A/zh active Pending
- 2016-03-03 CA CA2978457A patent/CA2978457A1/en not_active Abandoned
- 2016-03-03 AU AU2016226087A patent/AU2016226087A1/en not_active Abandoned
- 2016-03-03 BR BR112017018932A patent/BR112017018932A2/pt not_active Application Discontinuation
- 2016-03-03 WO PCT/US2016/020768 patent/WO2016141234A1/en not_active Ceased
- 2016-03-03 KR KR1020177027376A patent/KR102684690B1/ko active Active
- 2016-03-03 SG SG11201707151YA patent/SG11201707151YA/en unknown
-
2017
- 2017-08-31 IL IL254241A patent/IL254241A0/en unknown
- 2017-09-01 CL CL2017002226A patent/CL2017002226A1/es unknown
- 2017-09-04 PH PH12017501589A patent/PH12017501589A1/en unknown
-
2023
- 2023-04-28 US US18/309,466 patent/US20230365638A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017011345A (es) | 2018-04-24 |
| KR20170121262A (ko) | 2017-11-01 |
| US20230365638A1 (en) | 2023-11-16 |
| CN108024522A (zh) | 2018-05-11 |
| JP2018506984A (ja) | 2018-03-15 |
| US20180037620A1 (en) | 2018-02-08 |
| WO2016141234A1 (en) | 2016-09-09 |
| KR102684690B1 (ko) | 2024-07-15 |
| EP3264891A4 (en) | 2018-09-05 |
| BR112017018932A2 (pt) | 2018-07-31 |
| CA2978457A1 (en) | 2016-09-09 |
| PH12017501589A1 (en) | 2018-02-05 |
| SG11201707151YA (en) | 2017-09-28 |
| EP3264891A1 (en) | 2018-01-10 |
| IL254241A0 (en) | 2017-10-31 |
| RU2017132331A (ru) | 2019-04-03 |
| US11673928B2 (en) | 2023-06-13 |
| CL2017002226A1 (es) | 2018-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230365638A1 (en) | Etv2 and uses thereof | |
| US20200017882A1 (en) | Engineering of humanized car t-cell and platelets by genetic complementation | |
| JP2019502400A (ja) | キメラ胚補助臓器作製用の組成物及び方法 | |
| Matsunari et al. | Transgenic pigs with pancreas-specific expression of green fluorescent protein | |
| US20210037797A1 (en) | Inducible disease models methods of making them and use in tissue complementation | |
| US20190254266A1 (en) | Engineering of Humanized Kidney by Genetic Complementation | |
| JP2018522553A (ja) | ヒト化骨格筋 | |
| JP2018523999A (ja) | ヒト化心筋 | |
| JP2019092391A (ja) | 生殖細胞欠損動物を用いる遺伝子改変動物の作製方法 | |
| Suvá et al. | Use of an exogenous DNA-free system to generate MSTN-KO calves by CRISPR/Cas9 and SCNT | |
| JP5771240B2 (ja) | 免疫不全ブタ | |
| HK1255301A1 (en) | Etv2 and uses thereof | |
| KR101437590B1 (ko) | 사람 ｃｄ７３ 발현 벡터, 이를 포함하는 세포주 및 형질전환 복제동물 | |
| JP2019517818A (ja) | 体細胞核移植（ｓｃｎｔ）細胞および胚盤胞補完を用いた組織再生法 | |
| KR20190036865A (ko) | 세포질 이식을 이용한 복제배아의 재프로그래밍 효율 향상 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |